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Abstract
Background:  Survivin is a structurally and functionally unique member of the inhibitor of
apoptosis protein (IAP) family. It plays an important role, not only in regulating mitosis but also in
inhibiting apoptosis. The current literature contains few reports on the transcriptional regulation
of survivin expression in lung cancer.
Methods: In this study, we investigated the effect of hypoxia-inducible factor-1α (HIF-1α) on the
transcriptional activity of the survivin promoter in non-small cell lung cancer (NSCLC).
Immunohistochemical staining was used to detect the expression of survivin and HIF-1α in the lung
tissue of 120 patients with non-small cell lung cancer (NSCLC) and 40 patients with benign
pulmonary disease. We also performed experiments with the lung adenocarcinoma cell line A549
cells, which were cultured under hypoxic conditions. The expression of survivin and HIF-1α was
detected by real-time RT-PCR and Western blotting. In the survivin promoter the putative binding-
site for HIF-1α, is -19 bp~-16 bp upstream of TSS. We performed site-directed mutagenesis of this
binding site, and used luciferase reporter plasmids to determine the relative activity of the survivin
promoter in A549 cells. We also studied the effect of HIF-1α on the expression of survivin by
dsRNA targeting of HIF-1α mRNA.
Results: HIF-1α (58.33%) and survivin (81.60%) were both over-expressed in NSCLC and their
expressions correlated with one another. They were also expressed in A549 cells under normal
and hypoxic conditions, with a significant increase under hypoxic conditions. Site directed
mutagenesis of the putative binding site for HIF-1α in the survivin promoter significantly decreased
the activity of the survivin promoter in A549 cells. Inhibition of HIF-1α by RNAi decreased the
expression of survivin in A549 cell lines.
Conclusion: Our results indicate that the binding of HIF-1α to the survivin promoter increases
transcription of the survivin gene. Thus, HIF-1α is an important transcriptional regulator of survivin
expression
Background
Survivin is a structurally and functionally unique member
of the inhibitor of apoptosis protein (IAP) family. It plays
an important role not only in regulating mitosis but also
in inhibiting apoptosis [1,2]. Moreover, it is highly
expressed in almost all types of human tumors and fetal
tissues but barely detectable in normal adult tissues [3,4].
High levels of survivin expression have been associated
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with tumor progression and angiogenesis, resistance to
radiation and drug treatments, and poor survival rates in
cancer patients [5,6]. Different approaches aimed to target
survivin, including small interfering RNAs [7], dominant
negative mutants [8], antisense oligonucleotides [2],
ribozymes [9,10], and triplex DNA formation [11], have
been used for cancer treatment. However, none of these
studies focus on transcriptional inhibition of survivin as a
potential approach for cancer treatment. Due to the mul-
tiple functions of survivin, it seems that transcriptional
inhibition of survivin could be an important mechanism
to inhibit survivin expression for cancer treatment
[12,13].
Much effort has been made to explore the mechanisms by
which survivin transcription is regulated. A previous
report indicates that the survivin gene promoter is TATA-
less and contains GC-rich sequences. Additionally, the
Sp1 transcription factor induces survivin expression in
HeLa cells [14]. The core promoter of survivin contains
multiple CACCC or GGGTG motifs for binding of Sp1-
like proteins and Kruppel-like factors (Sp/KLF) [3]. For
example, KLF5, a member of Sp/KLF family, was found to
be a stimulator for survivin expression in Acute Lymphob-
lastic Leukemia [15]. However, there are few reports
related to the transcriptional regulation of survivin in lung
cancer and the precise molecular mechanism of survivin
transcriptional regulation remains unclear.
Poor oxygenation (hypoxia), owing to an inadequate
blood supply, is a common feature of most solid human
tumors and is associated with increased malignancy,
resistance to therapy and distant metastasis [16]. Hypoxia
inducible factor-1α (HIF-1α), a member of basic helix-
loop-helix-PAS protein family [17,18], is usually
increased under hypoxic conditions, and can activate tran-
scription of many genes that are critical for cellular func-
tion under hypoxic conditions [17]. Previous studies have
found that down-regulation of HIF-1α could significantly
decrease the levels of survivin expression in BxPc-3 pan-
creatic cancer cells [19] and breast cancer cells [20]. These
data indicated that HIF-1α regulates expression of sur-
vivin. However, there are very few studies on mechanisms
of survivin expression regulated by HIF-1α. Recently, Peng
et al demonstrated that HIF-1α could directly bind to the
survivin promoter, which strongly suggests that survivin
gene expression is indeed mediated by f HIF-1α under
normoxic conditions [20]. Nonetheless, there are still no
related reports in lung cancer.
In the present study, we examined the expression of HIF-
1α and survivin in tumor tissue from patients with non-
small cell lung cancer (NSCLC) as well as in a NSCLC cell
line derived from human lung adenocarcinoma (A549).
We found that HIF-1α and survivin were widely expressed
in both A549 cells and fresh NSCLC tissue samples and
that HIF-1α expression was consistently associated with
high levels of survivin expression in the lung cancer sam-
ples. By analyzing the survivin promoter activity, we fur-
ther found that HIF-1α was a transcriptional activator of
the survivin gene.
Methods
Tissue Specimens
Tissue samples were obtained from patients with a patho-
logical diagnosis of NSCLC as determined by two pathol-
ogists. Patients were operated on in Department of
Thoracic Surgery, the First Affiliated Hospital, Bengbu
Medical College during the period from March 2005 to
November 2007. There were 160 patients who signed
informed consent forms to participate in the study,
among them 120 NSCLC patients, 40 patients with
benign pulmonary disease (36 chronic inflammation, and
1 case each of pulmonary haemorrhage, pulmonary fibro-
sis, inflammatory pseudotumor, and hamartoma).
Patients received no chemotherapy or radiotherapy before
operation. The patients characteristics: male 94, female
26; age 42–76, average 61 years old; histology: squamous
cancer 100 cases, adenocarcinoma 20 cases; well-differen-
tiated cancer 45 cases, moderately differentiated cancer 46
cases and poorly differentiated cancer 29 cases; TNM stag-
ing: 43 cases in stage I-II and 77 cases in stage III according
to 1997 revised version of lung cancer staging standard by
International Union Against Cancer (UICC). All of the
patients had complete follow-up data and received con-
ventional post-surgery chemotherapy. The principle com-
mittee of the First Affiliated Hospital of Bengbu Medical
College had authorized this research.
Reagents
Goat anti-human survivin monoclonal antibody and anti-
human HIF-1α monoclonal antibody were purchased
from Santa Cruz (Santa Cruz, CA, USA). Lipofectamine™
2000 and Trizol were purchased from Invitrogen
(Carlsbad, CA, USA). pGEM-T-EASY vector, pGL3-basic
vector, pGL3-control vector, pRL-Tk vector and the Dual-
Luciferase® Reporter Assay System were purchased from
Promega (Madison, WI, USA). Universal Gene DNA
Extraction Kit Ver.3.0, PrimeScript™ RT-PCR KIT, Agarose
Gel DNA Purification kit2.0, Minibest Plasmid Purifica-
tion kit 2.0, TaKaRa MutanBEST Kit, PrimerSTARTM HS
DNA Polymerase, SYBR PrimeScript™ RT-PCR Kit were
purchased from Takara BioTechnology Co., Ltd (Dalian,
China). The dATP was purchased from Fermentas (Burl-
ington, Canada). Primers were synthesized by Sangon
Biological Engineering Technology & Services Co., Ltd
(Shanghai, China).
Cell line and culture
Human lung adenocarcinoma cell line A549 was main-
tained in Dulbecco's modified Eagle's medium (DMEM),
supplemented with 10% fetal bovine serum (Invitrogen,),Journal of Experimental & Clinical Cancer Research 2009, 28:29 http://www.jeccr.com/content/28/1/29
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100 units/ml of penicillin and 100 mg/ml of streptomy-
cin (Invitrogen) in a humid atmosphere incubator with
5% CO2 at 37°C. To study the expression of survivin
induced by hypoxia, A549 cells were incubated in hypoxic
condition (1% O2, 5% CO2 and 94% N2) for 24 h.
Immunohistochemistry
Immunohistochemical staining using the streptavidin
peroxidase method (S-P method) was performed on 4-μm
sections of paraffin-embedded specimens to detect expres-
sion of survivin and HIF-1α protein in NSCLC and benign
lung disease tissues. In brief, after deparaffinization and
hydration, the slides were treated with endogenous perox-
idase in 0.3% H2O2 for 30 min, after which the sections
were blocked for 2 hrs at room temperature with 1.5%
blocking serum in phosphate-buffered saline (PBS). Sec-
tions were then incubated with anti-Survivin antibody
(1:200 dilution) or anti-HIF-1α antibody (1:200 dilution)
at 4°C overnight., followed by washing in PBS, and incu-
bation with secondary anti-mouse biotinylated antibody
(1 : 2000) in PBS for 30 min at 37°C. Antibody binding
was detected using the streptavidin-biotin-peroxidase
complex/HRP, Code K0377 (Dako), with 3,3 diami-
nobenzidine for 3 min as a chromogenic substrate.
Finally, the slides were lightly counterstained with hema-
toxylin. As a negative control, duplicate sections were
immunostained without exposure to primary antibodies.
The results were observed under a light microscope.
PCR-based Site Directed Mutagenesis of survivin promoter
Genomic DNA of A549 cells was extracted with Universal
gene DNA extraction kit ver.3.0 according to the manufac-
turer's instructions. Survivin core promoter 230 bp (-203
~ +27 bp) was amplified by PCR using primers with
sequences selected from the survivin core promoter
sequence; (Forward: 5'-ATC GAC GCG TTC TTT GAA AGC
AGT CGA GGG GGC-3', Reverse: 5'-CCC AAG CTT TCT
GGC GGT TAA TGG CGC GCC-3',). The cycling parame-
ters were 95°C for 10s as a pre-denature step, followed by
40 cycles of 95°C for 5s, and 55°C for 30s, 72°C for 10
min. PCR products were purified, a polyadenylated by T4
DNA ligase, and then cloned to T-vector, named pGEM-T-
EASY-sur230 bp. The template for site-directed mutagene-
sis was pGEM-T-EASY-sur230 bp. The forward and reverse
primers (Forward: 5'-AGC GCT CCC GAC ATG CCC CGC
GGC-3', Reverse: 5'-GCC CTCTTA GGC GGT CCA C-3')
were used for PCR amplification. The cycling parameters
were 30 cycles of 95°C for 10s, 60°C for 5s, 72°C for 30s.
The linear product was self ligated after a blunting kina-
tion reaction; the product was named pGEM-T-EASY-
sur229 bp and confirmed by sequencing.
Construction of survivin promoter-luciferase reporter 
vectors, and transfection into A549 cells
The mutant, and normal constructs were removed from
pGL3-basic by restriction endonuclease Mlu I/Hind III.
The reporter vectors were constructed by T4 DNA ligase,
named pGL3-SVP-229-luc (mutant) and pGL3-SVP-230-
luc (normal). A549 cells were plated onto 6-well plates
one day prior to transfection. Following confirmation of
70%–80% confluence, the cells were transfected with
pGL3-Basic without promoter (negative control), pGL3-
SVP-229-luc (mutant plasmid), and pGL3-SVP-230-luc
(normal plasmid). For cell transfection, A549 cells were
transiently transfected with 2 μg plasmids and 0.2. g inter-
nal control plasmid pRL-TK by using Lipofectamine
2000™ reagent according to the manufacturer's instruc-
tions.
Luciferase reporter gene expression detection
Thirty hours after transfection, cells were harvested and
lysed with 1 × lysis buffer (Promega), and then 20 μl of
cell extract was assayed for luciferase activity using the
Dual-Luciferase assay kit (Promega) according to the
manufacture's instructions. The relative level of reporter
gene expression was expressed as the ratio of firefly luci-
ferase activity to Renilla luciferase (LU/RL).
RNA interference
A double strand siRNA oligonucleotide targeting HIF-1α
(sense: 5-CUGAUGAC CAGCAACUUGAdTdT-3, anti-
sense: 5-UCAAGUUGCUGGUCAU CAGdTdT-3) was
designed based on the reference [21] and synthesized by
Shanghai Genepharma Co. Ltd. (China). A pair of nega-
tive control siRNA were also designed with sequences dif-
ferent from siRNA-HIF-1α and not homologous to any
sequences found in gene bank (sense: 5-AGUUCAAC-
GACCAGUAGUCdTdT-3, antisense: 5-GACUACUG-
GUCGUUGA dTdT-3). For transfection, cells were plated
onto 10 cm2 cell culture dishes and grown to 30–50%
confluence before transfection. 50 μl of Oligofectamine
transfection reagent per dish (Invitrogen) was added, and
the cells were incubated at room temperature for 20 min.
The cells were then rinsed with Opti-Mem I to remove any
residual serum. The siRNA duplexes were diluted to a final
concentration of 20 nM in Opti-Mem I (Invitrogen). Cells
were incubated with the oligonucleotide duplexes in
serum-free conditions for 4 h at 37°C. Serum was then
added back to the culture, and cells were incubated in nor-
moxic or hypoxic condition for an additional 48 h.
Real Time Reverse Transcription-PCR
Total RNAs were isolated using Trizol reagent (Invitrogen)
according to the manufacturer's instruction. Twenty-five
nanogram total RNA per sample was reverse transcribed
by using the Reverse Transcription Reaction Kit (Takara
Code: DRR061S) according to the manufacturer's instruc-
tions. Quantitative real-time PCR was performed ana-
lyzed on the Applied Biosystems 7300 Real-Time PCR
System to determine the relative amounts of survivin,
HIF-1α and GAPDH (internal control) mRNAs expressed.
The SYBR Green Supermix was used for all real-time PCRJournal of Experimental & Clinical Cancer Research 2009, 28:29 http://www.jeccr.com/content/28/1/29
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reactions. The primers used in this study were: forward: 5'-
AGCCA GACGATCAT GCAG CTACTA-3 ', and reverse: 5'-
TGTGGTAAT CCACTTT CATC CAT TG-3 ' for HIF-1α PCR
product (167 bp); forward: 5'-AGGTCATCTCGGCTGTTC-
CTG-3', and reverse: 5'-TCATCCTCACTGCGGCT GTC-3',
for survivin PCR product (147 bp); and forward: 5'-
GGTCTCCTCTGAC TTCAACA-3', and reverse: 5'-
AGCCAAATTC GTTGTCATAC-3' for GAPDH PCR product
(116 bp). The quantitative real-time PCR PCR parameters
were 95°C for 10s as a pre-denature step, followed by 40
PCR cycles of 95°C for 5 s and 60°C for 30 s, and 72°C
for 10 min. Data presented in this study was collected at
60°C applying a threshold of 0.002 and normalized to
GAPDH using the default RQ ddCt study software.
Western Blot Analysis
After treatment, cells were washed two times with ice-cold
PBS and then lysed by Cell Lysis Solution (DSL, USA).
Cell lysates were incubated for 20 min at -20°C, and then
centrifuged at 13,000 g for 20 min at 4°C. Supernatants
were collected and protein concentration was determined
by the Bradford method. Fifty microgram of protein from
each sample was subjected to SDS-PAGE. After electro-
phoresis, proteins were transferred from the gel to polyvi-
nylidene difluoride (PVDF) membranes (Millipore MA,
USA). After blocking in a solution of 5% non-fat dry milk
diluted in TBS, the membranes were washed, and incu-
bated with primary antibodies [goat anti-survivin (1/
200), rat anti HIF-1α (1/200), or rat anti-β-actin (1/800)]
for 3 h at room temperature. After washing, the mem-
branes were incubated with the appropriate horseradish
peroxidase-labelled secondary antibody (1/2000) for 1 h.
Blots were developed using a chemiluminescent detection
system (ECL, Amersham Biosciences, Buckinghamshire,
UK).
Statistical analyses
The samples were analyzed by Q test, analysis of variance
and Chi-square tests to determine whether there were sig-
nificant differences between individual groups. The corre-
lation of survivin and HIF-lα protein in NSCLS was
analyzed by Spearman correlation analysis. All the tests
were performed using SPSS 11.5, and p < 0.05 was consid-
ered significant.
Results
Expression of survivin and HIF-1  in NSCLC and benign 
lung disease tissues
Survivin and HIF-lα proteins were detected and localised
in paraffin-embedded human lung tissue sections using
immunohistochemistry. Survivin was predominantly
expressed in the cytosol of the tumour cells with some
nuclear staining (Fig. 1C). Survivin was exclusively
expressed in lung cancer tissue (Fig. 1C, E, 81.60%,) and
not in benign lung disease tissue (Fig. 1A, E, 18.4%). The
specificity of survivin protein in lung cancer was 100%.
HIF-lα was found primarily in the cytosol of lung cancer
cells, with some nuclear staining (Fig. 1D). Positive rate of
HIF-lα in lung cancer tissue samples was 58.33% (70/
120), higher than that in tissue samples from benign lung
disease (10%, 4/40) (Fig. 1B, E, p < 0. 01). The expression
of survivin or HIF-1α in NSCLC was not correlated with
age or sex, but with differentiation grade, lymph node
metastasis and disease stages (Table 1). Spearman correla-
tion analysis showed a correlation between the expression
of survivin and the expression of HIF-1α in (rs = 0.255, p
= 0.005) (Table 1).
Hypoxia induces expression of HIF-1  and survivin
When A549 cells were incubated in hypoxic conditions
for 24 h, the expression of HIF-1α (2B, C, D) and survivin
Table 1: The correlation of survivin and HIF-1α expression with clinical pathology in NSCLC.
HIF-1α protein Survivin protein
Clinical Pathology N positive positive rate (%) p positive positive rate (%) p
sex
male 94 56 59.6 >0.05 79 84.0 >0.05
female 26 14 53.8 19 73.1
age
≤60 67 41 61.2 >0.05 52 77.6 >0.05
>60 53 29 54.7 46 86.8
degree of differentiation
high 45 19 42.2 <0.01 31 68.9 <0.01
moderate 46 29 63.0 39 84.8
low or undifferentiation 29 22 75.9 28 96.6
clinical stage
I~II 43 18 41.9 <0.01 29 72.1 <0.01
III 77 52 67.5 69 87.0
lymph nodes metastasis
yes 73 49 67.1 <0.01 66 90.4 <0.01
no 47 21 44.7 32 68.1
Survivin Positive** 98 63 90(63/70) = 0.005
Note: ** : rs = 0.255, p = 0.005.Journal of Experimental & Clinical Cancer Research 2009, 28:29 http://www.jeccr.com/content/28/1/29
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(2A, C, D) were detected by quantitative real time, reverse
transcription-PCR (2A, B) and western blot (2 C, D). As
shown in Fig 2, the expression of survivin and HIF-1α was
increased significantly in hypoxia as compared to nor-
moxia (p < 0.01).
Site directed mutagenesis of HIF-1  binding site on the survivin 
promoter decreases transcription activity of the survivin promoter
To determine whether the binding-site of HIF-lα can affect
the transcription of survivin in A549 cells, the GTGC
sequence in -19 ~ -16 bp of survivin promoter (Fig. 2A)
was changed to AGC by site-directed mutagenesis, and the
relative activity of the normal and mutated survivin pro-
moter were detected by luciferase activity assay. As shown
in Fig. 3, the relative activity of the normal sequence
(pGL3-SVP230-luc) was significantly higher than that of
both the mutated sequence (pGL3-SVP229-luc) and the
negative control group in the A549 cells (p  < 0.01).
Another HIF-1α binding site, located at -166 bp~-163 bp
of the survivin core promoter, was also mutated, but there
was no relative difference in transcriptional activity
between the normal and mutated binding site promoter
constructs.
Decreased HIF-1  expression leads to decreased survivin 
expression in A549 cells
A549 cells were treated with dsRNA (siRNA) targeted to
HIF-1α mRNA and the expression levels of HIF-1α and
survivin mRNA, and protein in were detected. As shown
in Fig. 4, the mRNA and protein expression levels of HIF-
1α and survivin in A549 cells significantly decreased after
the treatment with HIF-1α siRNA as compared with nega-
tive control siRNA and untreated controls (p < 0.05).
Discussion
Apoptosis has negatively regulates the occurrence and
development of tumors and prevents the rapid growth of
tumor cells. Apoptosis is co-regulated by apoptosis-pro-
moting factor and apoptosis-inhibiting factors (such as
members of the IAP family of proteins) [22,23]. Survivin,
the smallest protein of IAP family, is rarely expressed in
differentiated tissues and highly express in 75 ~ 96% of
Expression of survivin and HIF-1α in NSCLC and benign lung  disease tissues Figure 1
Expression of survivin and HIF-1α in NSCLC and 
benign lung disease tissues. Survivin and HIF-lα protein 
were detected and localised within paraffin-embedded human 
lung tissue using immunohistochemistry. A and B represent 
the negative expression of survivin protein and HIF-1α pro-
tein, respectively, in benign lung disease tissues. C and D rep-
resent the positive expression (arrow) of survivin protein 
and HIF-1α protein, respectively, in NSCLC,. E: The graph 
shows the statistical results. 81.60% (98/120) of lung cancer 
tissue samples were positive for survivin staining, and 58.33% 
(70/120_) of lung cancer tissue samples were positive for 
HIF-1α staining. ** p < 0.01.
Hypoxia induces expression of HIF-1α and survivin Figure 2
Hypoxia induces expression of HIF-1α and survivin. 
A549 cells were cultured in 10% FBS medium under hypoxic 
or normoxic conditions for 24h. The relative levels of sur-
vivin (A) and HIF-1α (B) to GAPDH mRNA were deter-
mined by quantitative real time, reverse transcription-PCR. 
C: The expression of survivin and HIF-1α protein in A549 
cells following HIF-1α-siRNA treatment as detected by 
Western blot analysis. D: The graph shows the statistical 
results of relative expression level of survivin and HIF-1α to 
β-actin protein. Data are given as means ± SD, n = 3, ** p < 
0.01.Journal of Experimental & Clinical Cancer Research 2009, 28:29 http://www.jeccr.com/content/28/1/29
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tumor tissues [4]. In this study, we found that survivin was
expressed in 81.6% of NSCLC tissues, and not expressed
in tissues from patients with benign lung diseases. The
expression of suvivin in the lung cancer tissue samples
was related to the differentiation, lymph node metastasis
and clinical stage of the cancer. These data suggest that
survivin plays an important role in prompting the devel-
opment of lung cancer.
In recent years, studies have showed that the activity of
survivin promoter in tumor cells is significantly increased
[24-27]. This suggests that the expression of survivin is
transcriptional regulated. Reduction of promoter activity
could significantly decrease the mRNA and thus decrease
the protein expression of survivin. Although the survivin
promoter contains several GC boxes, but methylation of
these GC boxes has not been found in the survivin pro-
moter. It is implicit that the regulation of survivin expres-
sion is at the level of transcription but it is still unclear
how survivin transcription is regulated by the Cis-acting
elements.
HIF-1α is highly expressed in various tumor tissues and
plays an important role in regulating hypoxia, and tumor
invasion and progress [17,19,20]. In this study, we con-
firmed that HIF-1α is highly expressed in NSCLC tissue, as
was found in breast cancer [28]. The expression of HIF-1α
is related to differentiation, lymph node metastasis and
clinical stage of lung cancer. Correlation analysis showed
the expression of survivin was positively correlated with
HIF-1α. The previous studies have showed that HIF-1α is
intermediate link in the evolution of the tumor, and this
protein could regulate a variety of hypoxia-induced gene
expression [29]. In vitro, we also found that the expres-
sions of HIF-1α and survivin in A549 cells were signifi-
cantly increased under hypoxic conditions. Therefore, we
speculated that HIF-1α might be a transcriptional activa-
tor of survivin. An early study using bioinformatic analy-
sis of the survivin  promoter 5'-upstream non-coding
region found that the survivin gene TSS (transcriptional
start site) was located in -64 bp upstream of translation
initiation codon (ATG). This bioinformatic analysis also
showed that the potential transcription factors that could
Site directed mutagenesis of the HIF-1α binding site on the  survivin promoter decreases transcription activity of the sur- vivin promoter Figure 3
Site directed mutagenesis of the HIF-1α binding site 
on the survivin promoter decreases transcription 
activity of the survivin promoter. A: Nucleotide 
sequence of the survivin promoter. The putative binding sites 
for transcription factor are boxed. The GTGC sequence in -
19 ~ -16 bp of survivin promoter was changed to AGC by 
mutation. B: A549 cells were transfected with pGL3-Basic 
without promoter (negative control), pGL3-SVP-229-luc 
(mutant plasmid), and pGL3-SVP-230-luc (normal plasmid). 
The relative activity of survivin promoter was analyzed by 
luciferase assay. The graph shows the statistical results. Data 
are given as means ± SD, n = 3, ** p < 0.01.
Decreased HIF-1α expression leads to decreased survivin  expression in A549 cells Figure 4
Decreased HIF-1α expression leads to decreased sur-
vivin expression in A549 cells. Cells were cultured in 
10% FBS medium overnight, followed by treatment with HIF-
1α-siRNA for 48 h. Total RNAs were isolated and analyzed 
by quantitative, real time, reverse transcription-PCR to 
determine the changes of survivin (A) and HIF-1α (B) mRNA. 
The relative levels of survivin and HIF-1α mRNA are 
expressed as a ratio of the amount of survivin (A) or HIF-1α 
(B) PCR products to the amount of GAPDH PCR product. 
C: The expression of survivin and HIF-1α protein in A549 
cells following HIF-1α-siRNA treatment as detected by 
Western blot analysis. The relative expression levels of HIF-
1α (D) and survivin (E) protein is expressed as a ratio of the 
amount of survivin or HIF-1α protein to the amount of β-
actin protein. Data are given as means ± SD, n = 3, ** p < 
0.01. Data are given as means ± SD, n = 3, ** p < 0.01.Journal of Experimental & Clinical Cancer Research 2009, 28:29 http://www.jeccr.com/content/28/1/29
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bind to the survivin promoter included Sp1, E2F, p53,
CDE, CHR, etc [14]. Our study detected that there are also
2 putative binding sites for HIF-1α, which are located at-
16 bp to -19 bp and at -133 bp to -136 bp in the proximal
promoter region of human survivin gene. The first site (16
bp to -19 bp) partially overlaps with one of the potential
Sp1 binding sites. Peng et al [20] also confirmed that there
is a putative HIF-1α binding site in the survivin core pro-
moter (-203 to +27). They also found that in breast cancer
cells, HIF-1α, induced by EGF, could bind to this putative
binding-site under hypoxic or normoxic conditions and
that when HIF-1α is bound to its binding site in the sur-
vivin promoter the expression of survivin is increased
[20]. In order to investigate if there are similar transcrip-
tional regulation mechanisms in lung cancer, we con-
structed two reporter constructs; one with the normal
putative binding site of HIF-1α (-19 bp ~-16 bp) in the
survivin core promoter and another with a mutated form
of this binding site. These constructs were then transfected
into A549 lung cancer cells. The results showed that the
relative activity of the mutation of this HIF-1α binding
site reduced transcriptional activity by 36.60%. Another
HIF-1α binding site, located at -166 bp~-163 bp of the
survivin core promoter was also mutated, but there was
no relative difference in transcriptional activity between
the normal and mutated binding site promoter constructs
(data not show). These data suggest that the site locating
at -19 bp ~-16 bp is one of the key cis-acting elements of
survivin core promoter.
To further prove that survivin could be induced by HIF-
1α, we used RNAi to silence the expression of HIF-1α. Our
results showed that the RNAi significantly decreased the
expression of HIF-1α mRNA and protein in A549 cells,
and that this decrease of HIF-1α correlated with the
decreased expression of survivin. This suggests that inhib-
iting expression of the HIF-1α gene can decrease the
expression of survivin, and that HIF-1α might be an
important transcription factor involved in the regulation
of survivin mRNA expression.
Conclusion
In summary, our experimental results demonstrated that
HIF-1α and survivin are highly expressed in non-small
cell lung cancer and lung adenocarcinoma cell line A549
cells, and that the expression of these proteins correlated
with one another. Additionally, we show that hypoxia
could induce the expression of HIF-1α and survivin. Fur-
thermore, the data presented here demonstrate that the
potential binding site of HIF-1α on survivin promoter has
a positive role in the regulation of transcriptional activity
of the survivin gene, HIF-1α may be an important tran-
scription factor involved in regulation of survivin expres-
sion.
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